ALFA Finder| Revenue growth | FY26 income ₹4,488cr (+7.6% YoY); Q4FY26 (+11.2% YoY). |
|---|---|
| Margins | Adj. EBITDA margin improved to 12.0% in FY26. |
| Demand visibility | 200Mn Euro CDMO contract provides long-term revenue visibility. |
| Management confidence | Strong confidence in European CDMO and Zambia JV execution. |
Growth
FY26 Revenue up 5.8% to ₹4,359cr; Adj. PAT up 27.3% to ₹276cr.
Outlook
FY28 European CDMO supplies start; Zambia facility operational FY29; expansion into Oncology/Steroid lines.
Risks
API price erosion, prolonged low domestic volume growth, and losses in trade generics/API segments.
Earnings Call filed with BSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹768.80
- Market cap
- ₹12,100 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 33.3×Sector 43.8×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.
- Value
- ₹680.0 Cr
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.